IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques

References

• Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 2011; 1:233 - 40; http://dx.doi.org/10.1016/j.coviro.2011.08.003; PMID: 22440782
   PubMed Web of Science ®Google Scholar
• Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997; 71:4892 - 903; PMID: 9188551
   PubMed Web of Science ®Google Scholar
• Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis GN. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992; 66:7176 - 82; PMID: 1433510
   PubMed Web of Science ®Google Scholar
• Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992; 66:150 - 9; PMID: 1727477
   PubMed Web of Science ®Google Scholar
• Graf M, Deml L, Wagner R. Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med 2004; 94:197 - 210; PMID: 14959831
   PubMedGoogle Scholar
• Deml L, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001; 75:10991 - 1001; http://dx.doi.org/10.1128/JVI.75.22.10991-11001.2001; PMID: 11602739
   PubMed Web of Science ®Google Scholar
• Nasioulas G, Zolotukhin AS, Tabernero C, Solomin L, Cunningham CP, Pavlakis GN, et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994; 68:2986 - 93; PMID: 8151769
   PubMed Web of Science ®Google Scholar
• Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, von Gegerfelt A, et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 2011; 29:6742 - 54; http://dx.doi.org/10.1016/j.vaccine.2010.12.056; PMID: 21195080
   PubMed Web of Science ®Google Scholar
• de Arruda LB, Chikhlikar PR, August JT, Marques ET. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004; 112:126 - 33; http://dx.doi.org/10.1111/j.1365-2567.2004.01823.x; PMID: 15129672
   PubMed Web of Science ®Google Scholar
• Marques ET Jr., Chikhlikar P, de Arruda LB, Leao IC, Lu Y, Wong J, et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003; 278:37926 - 36; http://dx.doi.org/10.1074/jbc.M303336200; PMID: 12824194
   PubMed Web of Science ®Google Scholar
• Valentin A, Chikhlikar P, Patel V, Rosati M, Maciel M, Chang KH, et al. Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009; 27:4840 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.05.093; PMID: 19539586
   PubMed Web of Science ®Google Scholar
• Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002; 100:1153 - 9; http://dx.doi.org/10.1182/blood-2002-01-0086; PMID: 12149191
   PubMed Web of Science ®Google Scholar
• Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M, et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005; 79:8480 - 92; http://dx.doi.org/10.1128/JVI.79.13.8480-8492.2005; PMID: 15956591
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011; 23:421 - 9; http://dx.doi.org/10.1016/j.coi.2011.03.008; PMID: 21530212
   PubMed Web of Science ®Google Scholar
• Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R, et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2010; 28:4827 - 36; http://dx.doi.org/10.1016/j.vaccine.2010.04.064; PMID: 20451642
   PubMed Web of Science ®Google Scholar
• Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009; 106:15831 - 6; http://dx.doi.org/10.1073/pnas.0902628106; PMID: 19717425
   PubMed Web of Science ®Google Scholar
• Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, Bergamaschi C, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008; 26:5223 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.03.090; PMID: 18468743
   PubMed Web of Science ®Google Scholar
• Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, et al. Enhanced control of pathogenic SIVmac239 replication in macaques immunized with a plasmid IL12 and a DNA prime, viral vector boost vaccine regimen. J Virol 2011; 85:9578 - 87; http://dx.doi.org/10.1128/JVI.05060-11; PMID: 21734035
   PubMed Web of Science ®Google Scholar
• Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007; 81:5257 - 69; http://dx.doi.org/10.1128/JVI.00055-07; PMID: 17329330
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112 - 20; http://dx.doi.org/10.1016/j.vaccine.2008.02.036; PMID: 18430495
   PubMed Web of Science ®Google Scholar
• Vojnov L, Bean AT, Peterson EJ, Chiuchiolo MJ, Sacha JB, Denes FS, et al. DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells. Vaccine 2011; 29:7483 - 90; http://dx.doi.org/10.1016/j.vaccine.2011.07.048; PMID: 21839132
   PubMed Web of Science ®Google Scholar
• Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252; http://dx.doi.org/10.1371/journal.pone.0019252; PMID: 21603651
   PubMed Web of Science ®Google Scholar
• Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B’ HIV-1 candidate vaccine. PLoS One 2010; 5:e8617; http://dx.doi.org/10.1371/journal.pone.0008617; PMID: 20111582
   PubMed Web of Science ®Google Scholar
• Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007; 104:18648 - 53; http://dx.doi.org/10.1073/pnas.0709198104; PMID: 18000037
   PubMed Web of Science ®Google Scholar
• Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R, et al. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. Vaccine 2003; 21:629 - 37; http://dx.doi.org/10.1016/S0264-410X(02)00571-6; PMID: 12531331
   PubMed Web of Science ®Google Scholar
• Boyer JD, Maciag PC, Parkinson R, Wu L, Lewis MG, Weiner DB, et al. Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine 2006; 24:4498 - 502; http://dx.doi.org/10.1016/j.vaccine.2005.08.016; PMID: 16185790
   PubMed Web of Science ®Google Scholar
• Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS 2000; 14:1515 - 22; http://dx.doi.org/10.1097/00002030-200007280-00007; PMID: 10983638
   PubMed Web of Science ®Google Scholar
• Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Sidhu MK, et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005; 34:262 - 70; http://dx.doi.org/10.1111/j.1600-0684.2005.00124.x; PMID: 16128921
   PubMed Web of Science ®Google Scholar
• Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 2004; 22:1744 - 50; http://dx.doi.org/10.1016/j.vaccine.2004.01.036; PMID: 15068858
   PubMed Web of Science ®Google Scholar
• Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007; 25:4967 - 82; http://dx.doi.org/10.1016/j.vaccine.2006.11.070; PMID: 17335943
   PubMed Web of Science ®Google Scholar
• Egan MA, Chong SY, Megati S, Montefiori DC, Rose NF, Boyer JD, et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005; 21:629 - 43; http://dx.doi.org/10.1089/aid.2005.21.629; PMID: 16060834
   PubMed Web of Science ®Google Scholar
• Egan MA, Megati S, Roopchand V, Garcia-Hand D, Luckay A, Chong SY, et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 2006; 24:4510 - 23; http://dx.doi.org/10.1016/j.vaccine.2005.08.024; PMID: 16140439
   PubMed Web of Science ®Google Scholar
• Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008; 180:7969 - 79; PMID: 18523260
   PubMed Web of Science ®Google Scholar
• Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158:816 - 26; PMID: 8992999
   PubMed Web of Science ®Google Scholar
• Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, et al. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol 1999; 28:214 - 23; http://dx.doi.org/10.1111/j.1600-0684.1999.tb00272.x; PMID: 10593488
   PubMed Web of Science ®Google Scholar
• Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999; 19:77 - 84; http://dx.doi.org/10.1089/107999099314441; PMID: 10048771
   PubMed Web of Science ®Google Scholar
• Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28:1089 - 103; http://dx.doi.org/10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L; PMID: 9541605
   PubMed Web of Science ®Google Scholar
• Morrow MP, Yan J, Pankhong P, Ferraro B, Lewis MG, Khan AS, et al. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010; 17:1493 - 9; http://dx.doi.org/10.1128/CVI.00181-10; PMID: 20685940
   PubMed Web of Science ®Google Scholar
• Robinson TM, Sidhu MK, Pavlakis GN, Felber BK, Silvera P, Lewis MG, et al. Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses. J Med Primatol 2007; 36:276 - 84; http://dx.doi.org/10.1111/j.1600-0684.2007.00245.x; PMID: 17669216
   PubMed Web of Science ®Google Scholar
• Schadeck EB, Sidhu M, Egan MA, Chong S-Y, Piacente P, Masood A, et al. Plasmid encoded IL-12 functions as a DNA vaccine adjuvant and augments SIVgag-specific cell-mediated and humoral immune responses in Rhesus macaques. Vaccine 2006; 24:4677 - 87; http://dx.doi.org/10.1016/j.vaccine.2005.10.035; PMID: 16288822
   PubMed Web of Science ®Google Scholar
• Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006; 24:4677 - 87; http://dx.doi.org/10.1016/j.vaccine.2005.10.035; PMID: 16288822
   PubMed Web of Science ®Google Scholar
• Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D, et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008; 26:4819 - 29; http://dx.doi.org/10.1016/j.vaccine.2008.06.103; PMID: 18657584
   PubMed Web of Science ®Google Scholar
• O’Neill E, Bostik V, Montefiori DC, Kraiselburd E, Villinger F. IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. AIDS Res Hum Retroviruses 2003; 19:883 - 90; http://dx.doi.org/10.1089/088922203322493058; PMID: 14585220
   PubMed Web of Science ®Google Scholar
• Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, et al, NIAID HIV Vaccine Trials Network. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231; http://dx.doi.org/10.1371/journal.pone.0029231; PMID: 22242162
   PubMed Web of Science ®Google Scholar
• Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP, et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179:1273 - 83; http://dx.doi.org/10.1084/jem.179.4.1273; PMID: 7908322
   PubMed Web of Science ®Google Scholar
• Meyaard L, Hovenkamp E, Otto SA, Miedema F. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol 1996; 156:2776 - 82; PMID: 8609396
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541 - 8; PMID: 9326219
   PubMed Web of Science ®Google Scholar
• Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293 - 9; http://dx.doi.org/10.1038/nm.1935; PMID: 19219024
   PubMed Web of Science ®Google Scholar
• Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168:29 - 43; PMID: 11751943
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Ramírez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000; 74:6278 - 86; http://dx.doi.org/10.1128/JVI.74.14.6278-6286.2000; PMID: 10864637
   PubMed Web of Science ®Google Scholar
• Lasarte JJ, Corrales FJ, Casares N, López-Díaz de Cerio A, Qian C, Xie X, et al. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol 1999; 162:5270 - 7; PMID: 10228002
   PubMed Web of Science ®Google Scholar
• Lee K, Overwijk WW, O’Toole M, Swiniarski H, Restifo NP, Dorner AJ, et al. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J Interferon Cytokine Res 2000; 20:589 - 96; http://dx.doi.org/10.1089/10799900050044787; PMID: 10888115
   PubMed Web of Science ®Google Scholar
• Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD. IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. Blood 2011; 118:3890 - 900; http://dx.doi.org/10.1182/blood-2011-05-357111; PMID: 21832277
   PubMed Web of Science ®Google Scholar
• Killian MS, Johnson C, Teque F, Fujimura S, Levy JA. Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J Virol 2011; 85:1696 - 705; http://dx.doi.org/10.1128/JVI.01120-10; PMID: 21147929
   PubMed Web of Science ®Google Scholar
• Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012; 63:95 - 111; http://dx.doi.org/10.1146/annurev-med-042010-085643; PMID: 21942424
   PubMed Web of Science ®Google Scholar
• Frahm MA, Picking RA, Kuruc JD, McGee KS, Gay CL, Eron JJ, et al. CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol 2012; 188:4289 - 96; http://dx.doi.org/10.4049/jimmunol.1103701; PMID: 22461689
   PubMed Web of Science ®Google Scholar
• Holznagel E, Norley S, Holzammer S, Coulibaly C, Kurth R. Immunological changes in simian immunodeficiency virus (SIV(agm))-infected African green monkeys (AGM): expanded cytotoxic T lymphocyte, natural killer and B cell subsets in the natural host of SIV(agm). J Gen Virol 2002; 83:631 - 40; PMID: 11842258
   PubMed Web of Science ®Google Scholar
• Howe R, Dillon S, Rogers L, Palmer B, MaWhinney S, Blyveis N, et al. Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection. J Acquir Immune Defic Syndr 2009; 50:444 - 56; http://dx.doi.org/10.1097/QAI.0b013e31819aa8c4; PMID: 19360930
   PubMed Web of Science ®Google Scholar
• Nascimbeni M, Pol S, Saunier B. Distinct CD4+ CD8+ double-positive T cells in the blood and liver of patients during chronic hepatitis B and C. PLoS One 2011; 6:e20145; http://dx.doi.org/10.1371/journal.pone.0020145; PMID: 21647449
   PubMedGoogle Scholar
• Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 2004; 104:478 - 86; http://dx.doi.org/10.1182/blood-2003-12-4395; PMID: 15044252
   PubMed Web of Science ®Google Scholar
• Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C, et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 2010; 28:1962 - 74; http://dx.doi.org/10.1016/j.vaccine.2009.10.099; PMID: 20188252
   PubMed Web of Science ®Google Scholar
• Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 2009; 106:3952 - 7; http://dx.doi.org/10.1073/pnas.0813392106; PMID: 19225108
   PubMed Web of Science ®Google Scholar
• Moore JP, Wallace LA, Follett EA, McKeating JA. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 1989; 3:155 - 63; http://dx.doi.org/10.1097/00002030-198903000-00006; PMID: 2540772
   PubMed Web of Science ®Google Scholar
• Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010; 84:7161 - 73; http://dx.doi.org/10.1128/JVI.00410-10; PMID: 20444898
   PubMed Web of Science ®Google Scholar
• Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005; Chapter 12:Unit 12 1.
   Google Scholar
• Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117 - 34; http://dx.doi.org/10.1084/jem.20082831; PMID: 19414559
   PubMed Web of Science ®Google Scholar